



University of Dundee

Evaluation of coronary artery disease as a risk factor for reticular pseudodrusen

McCarter, Rachel V.; McKay, Gareth J.; Quinn, Nicola B.; Chakravarthy, Usha; MacGillivray, Tom J.; Robertson, Gavin; Pellegrini, Enrico; Trucco, Emanuele; Williams, Michelle C.; Peto, Tunde; Dhillon, Baljean; van Beek, Edwin Jr; Newby, David E.; Kee, Frank; Young, Ian S.; Hogg, Ruth E.

Published in:
British Journal of Ophthalmology

DOI:
[10.1136/bjophthalmol-2017-310526](https://doi.org/10.1136/bjophthalmol-2017-310526)

Publication date:
2017

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):
McCarter, R. V., McKay, G. J., Quinn, N. B., Chakravarthy, U., MacGillivray, T. J., Robertson, G., ... Hogg, R. E. (2017). Evaluation of coronary artery disease as a risk factor for reticular pseudodrusen. *British Journal of Ophthalmology*. DOI: 10.1136/bjophthalmol-2017-310526

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

1 **Evaluation of Coronary Artery Disease as a Risk Factor for**
2 **Reticular Pseudodrusen.**

3

4 *McCarter RV,¹ McKay GJ,¹ Quinn NB,¹ Chakravarthy U,¹ MacGillivray*
5 *TJ,² Robertson G,² Pellegrini E,² Trucco E,³ Williams MC,⁴ Peto T,¹*
6 *Dhillon B,² van Beek EJR,⁵ Newby DE,⁴ Kee F,^{1*} Young IS,^{1*} Hogg RE.^{1a}*

7

8 *¹Center for Public Health, Queen's University Belfast. ²VAMPIRE project,*
9 *Center for Clinical Brain Sciences, The University of Edinburgh.*
10 *³VAMPIRE project, Computing, School of Science and Engineering,*
11 *University of Dundee. ⁴Center of Cardiovascular Science, University of*
12 *Edinburgh. ⁵Clinical Research Imaging Center, University of Edinburgh.*

13 ** NICOLA Study Principal Investigator and Study Originator*

14

15 *^aCorresponding author: Dr Ruth E. Hogg*

16 *Center for Public Health, Queen's University Belfast, Institute of Clinical Science*
17 *Block A, Royal Hospital, Grosvenor Road, Belfast, Northern Ireland, BT12 6BA.*

18 *Email: r.e.hogg@qub.ac.uk*

19 *Word count: 3143*

20

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

ABSTRACT

Purpose: Reticular pseudodrusen (RPD) is a risk factor for late age-related macular degeneration (AMD). Associations between RPD and coronary artery disease (CAD) have been reported from small case-control studies. This study investigated the association of RPD within a predominantly CAD cohort.

Methods: A subgroup of subjects from a multicenter randomized controlled trial of computed tomography coronary angiography (CTCA) underwent ultra-widefield (UWF) retinal imaging CAD determined by CTCA was categorized as normal, non-obstructive or obstructive Specific AMD features in UWF images were graded Standardized grids were used to record the spatial location of AMD features, including RPD. Multivariate confounder adjusted regression models assessed the association between RPD and CAD.

Results: The 534 participants were aged from 27-75 years (mean 58 ±9 years; 425 (80%) ≥50 years) with a male preponderance (56%). Within the study sample, 178 (33%) had no CAD, 351 (66%) had CAD, 182 (34%) had hypertension and 42 (24%) had neither CAD nor hypertension. RPD was detected in 30 participants (5.6%) and bilaterally in 23. Most participants with bilateral RPD had drusen >125 µm (early AMD). After adjustment for potential confounders (age, sex, drusen >125 µm, smoking status), multivariate analysis found no significant association between CAD and RPD (odds ratio [OR] 1.31; 95% Confidence Interval [CI] (0.57-3.01); p=0.52). A significant association was identified between RPD and drusen >125 µm (OR 3.18; 95% CI (1.61-6.27); p=0.001).

44 **Conclusion:** We found no evidence to support an association between CAD
45 and RPD. RPD was strongly associated with early AMD features, when
46 present.

47 **INTRODUCTION**

48 Age-related macular degeneration (AMD) is the leading cause of permanent
49 blindness in the developed world with the most sight loss occurring in the late
50 stages, namely geographic atrophy (GA) and choroidal neovascularization (CNV).¹
51 Risk factors for progression from early to late AMD include advancing age,²
52 cardiovascular disease (CVD),³⁻⁵ obesity,⁶ cigarette smoking,⁷ ethnicity,⁸
53 hypertension,³ high cholesterol,⁹ genetic variants such as apolipoprotein E (*ApoE*)
54 gene,¹⁰ age-related maculopathy susceptibility 2 (*ARMS2*) gene,¹¹ complement
55 factor H (*CFH*)¹² and inflammatory markers such as C-reactive protein (*CRP*).¹³
56 Recently, reticular pseudodrusen (RPD) have been shown to be an important
57 independent risk factor for progression to both GA^{14,15} and CNV.^{14,16} In addition,
58 various risk factors have been reported to be associated with RPD including
59 advancing age, female gender, smoking, *ARMS2*, *C3*, *VEGFA* and *CFH* genetic
60 variants.¹⁷⁻¹⁹

61

62 The prevalence of RPD reported in the literature has varied depending on the study
63 design, the extent to which confounding variables are accounted for, and the imaging
64 modality used in its detection. Initial reports of the association came from data
65 collected on AMD cohorts recruited in hospital eye clinics and reported high
66 prevalences ranging from 29 - 52%.^{17, 20-22} Data from population based studies are
67 limited and show large variation, such as 0.4% from the Melbourne Collaborative
68 Cohort study to 4.9% in the Rotterdam study and 13% in the Alienor study.^{18,19,23}
69 Such varying estimates might be attributed to the different imaging and grading
70 protocols used.

71

72 The strong association between RPD and a thin choroid has prompted a spate of
73 small studies that have sought associations between RPD and cardiovascular
74 disease.²⁴⁻²⁸ Cymerman et al reported in a small prospective cohort of patients with
75 no known retinal disease recruited from a cardiovascular clinic; 23 participants with
76 coronary artery disease (CAD) had a higher frequency of RPD compared to 15 who
77 did not have CAD.²⁴ A literature review by Rastogi and Smith²⁵ on the association
78 between AMD, RPD with CVD highlighted studies reporting an association between
79 RPD and hypertension and angina.²⁶⁻²⁹ Smith and colleagues hypothesized that the
80 increased mortality from systemic-vascular disease that affects males more severely
81 compared to females, may account for the higher proportion of women with RPD that
82 has been observed in various population-based studies.²⁹ Notably this review
83 highlighted the potential importance of large prospective cohort studies sampling
84 participants >45 years with and without CAD to identify RPD development and
85 potential associations.²⁵

86

87 A sub-study of the SCOT-HEART (SH) trial that incorporated ultrawide field (UWF)
88 retinal imaging offered a unique opportunity to explore the relationship between CAD
89 and RPD. The use of widefield technology to evaluate the retinal fundus offered an
90 additional advantage as RPD is commonly located in the retinal arcades and beyond
91 ²⁶ and to date there is only one study that has estimated RPD prevalence that has
92 included central and peripheral retinal locations.³⁰ However the sensitivity of UWF to
93 detect RPD has not been established. We therefore first validated the methodology
94 using images from a population based epidemiological study (the Northern Ireland
95 Cohort of Longitudinal Ageing [NICOLA]) which captured both UWF, CFP, OCT,

96 infra-red and autofluorescence (AF) images of the retina and subsequently used the
97 SH trial sub-study UWF images to explore the relationship between RPD and CAD.
98

99 **MATERIALS AND METHODS**

100 **Validation of detection of RPD by UWF imaging**

101 Nine hundred consecutive participants were selected from the NICOLA Study. CFP
102 was performed on the Canon CX-1 Digital Fundus Camera (Canon U.S.A., Inc.,
103 Melville, NY, U.S.A.). Stereoscopic pairs centered on the optic disc and macula were
104 captured. CFP images were viewed and graded using the Oculab program (Digital
105 Healthcare Oculab, V3.7.98.0, Emis Health, Leeds, UK). UWF retinal imaging was
106 performed on the Optos Tx200 Scanning Laser Ophthalmoscope (Optos PLC,
107 Dunfermline, UK) using both color and AF acquisition modes. Images were viewed
108 and graded using the Optos V² Vantage Pro software (version 2.9.4.2). OCT images
109 were captured using the Heidelberg Spectralis SD-OCT/SLO (Heidelberg
110 Engineering, Heidelberg, Germany). Images were reviewed using the Heidelberg
111 eye explorer, HEYEX software version 1.9.10.0. Multimodal grading was undertaken
112 with display of the multicolor enface retinal image (includes infrared reflectance,
113 green reflectance and blue reflectance) centered on the fovea. The grading
114 distinguished the reticulated pattern visible on the en face images which were
115 classified as RPD from subretinal drusenoid deposits (SDD) which are the OCT
116 correlate seen on the high resolution OCT B scans. This distinction was made as
117 mild and subtle features of SDD can be present before RPD are seen on the en face
118 imaging modalities.

119 UWF images were graded for the presence or absence of RPD by a trained single
120 grader who was not involved in any other grading procedures with quality assurance

121 and review by a retina specialist (UC). Multimodal (CFP, MultiColor, AF and OCT
122 images) grading was undertaken by trained graders in the network of UK Reading
123 Center's (NetwORC UK) for the presence or absence of RPD. Detection of RPD on
124 any modality was taken as evidence of presence of this feature. Sensitivity and
125 specificity of the UWF imaging in detecting RPD compared to the RPD detected from
126 the NICOLA cohort's *en face* images was computed.

127

128 **The SCOT-HEART (SH) Study and Sample**

129 The SH trial (ClinicalTrials.gov, number NCT01149590) was a multicenter
130 randomized controlled trial undertaken in Scotland (2010-2014) on 4,146
131 participants, aged 18-75 years, drawn from 12 cardiology clinics across Scotland.³¹
132 The main aim of the study was to determine the role of multidetector computed
133 tomography in the diagnosis and management of patients attending rapid access
134 chest pain clinics. Participants were randomly assigned to either standard care
135 (control intervention) or standard care and the computed tomography coronary
136 angiography (CTCA) and calcium scores (intervention). CAD was categorized in the
137 SH study as: (i) obstructive CAD, atherosclerotic plaque encompassing a luminal
138 cross-sectional area of $\geq 70\%$ in at least one major epicardial vessel; (ii) non-
139 obstructive CAD, either atherosclerotic plaque encompassing a luminal cross-
140 sectional area of $< 70\%$ but $> 10\%$ in at least one major epicardial vessel, or a
141 calcium score > 400 AU (Agatston units) or > 90 th percentile for age and sex; or (iii)
142 minimal or no CAD. Non-obstructive disease was further sub-divided into mild (10-
143 50% luminal cross-sectional area) or moderate (50-70% luminal cross-sectional
144 area) stenosis. At two sites (Edinburgh and Dundee), consecutive patients were

145 approached to undergo UWF imaging immediately before or after undergoing CTCA.
146 We assessed 534 participants from a sub-study of SH who had UWF imaging
147 captured using two Optos P200C Scanning Laser Ophthalmoscopes (Optos PLC,
148 Dunfermline, UK) in addition to the normal study procedures at two sites (the Clinical
149 Research Imaging Center in Edinburgh and the Clinical Research Center Dundee).³²
150

151 **Image Grading in SH**

152 Specific features of AMD in UWF images were graded for AMD characteristics
153 (increased pigment, decreased pigment, drusen, maximum drusen size, reticular
154 pseudodrusen, GA and CNV) and other peripheral abnormalities using the 'Study-
155 specific Grading Procedures for OPERA Study,' guidelines (November 2013).³³ The
156 Optos software utilised a modified Studies of Ocular Complications of AIDS (SOCA)
157 optos peripheral retina AMD study (OPERA) grid (Figure 1) which was divided into
158 three zones: Zone 1 (posterior pole), Zone 2 (extends from Z1 to a circle through the
159 ampullae of the vortex veins) and Zone 3 (extends from Z2 to the outer periphery).
160 The Manchester grid was superimposed on the SOCA grid to estimate the
161 ungradable areas (Figure 2). In accordance with the OPERA guidelines, at least 50%
162 of the subfield should be visible to grade; if < 50% of the subfield was visible, it was
163 graded as "Cannot Grade." If AMD characteristics and other pathologies were
164 present in a Cannot Grade subfield, and if the grader was $\geq 90\%$ certain the lesion
165 was present, then grading was ascribed. Drusen presence was graded as follows:
166 absent; questionable; 1-5 drusen; 6-20 drusen; >20 drusen or cannot grade. The
167 maximum drusen size was graded as follows: < 125 μm ; $\geq 125\mu\text{m}$, < 250 μm distinct;
168 $\geq 125\mu\text{m}$, < 250 μm indistinct; $\geq 250\mu\text{m}$ distinct; $\geq 250\mu\text{m}$ indistinct or cannot grade.
169 RPD was graded as follows: absent; questionable; < 25% of subfield; 25-49% of

170 subfield; 50-74% of subfield; $\geq 75\%$ of subfield or cannot grade. RPD were defined
171 as yellow interlacing networks ranging from 125 μm to 250 μm in width or lesions
172 that occurred in regular well-defined domains (Figure 3). Images in which RPD were
173 questionable were arbitrated by a retinal specialist (UC).

174

175 **Statistical Analysis**

176 Statistical analyses were performed using IBM SPSS Statistics version 20
177 (Portsmouth, UK). Intraobserver agreement was calculated after 1 in 20 of the
178 images were randomly regraded for RPD and drusen using kappa (k) statistics,
179 which express the extent of agreement beyond chance. The interpretation of the k
180 statistic was as follows: 0, no agreement; 0 to 0.2, slight agreement; 0.21 to 0.40, fair
181 agreement; 0.41 to 0.60, moderate agreement; 0.61 to 0.8, substantial agreement;
182 and >0.81 , almost perfect agreement.³⁴

183

184 Univariate analysis (Chi-squared test or fisher's exact test for categorical variables
185 and independent t-test for continuous variables) was used to examine differences in
186 the demographic characteristics of participants according to presence or absence of
187 RPD. General estimating equations (GEE) which enabled data from both eyes to be
188 included were used to examine the association between RPD and CAD while
189 accounting for other factors identified as significant from the univariate analysis.

190

191 **RESULTS**

192 **Validation study**

193 UWF imaging detected 8 participants with reticular drusen (2 unilateral and 6
194 bilateral; 100% sensitivity).. Multimodal imaging (color, multicolor, infra-red and
195 autofluorescence) detected reticular drusen in 7 of those which were seen on *en*
196 *face* images The specificity of the UWF imaging was 99.9%. In one case, the UWF
197 imaging detected RPD beyond the field of view captured by the combination of
198 retinal imaging (Figure 4). The positive predictive value (PPV) was calculated at
199 87.5% and the negative predictive value (NPV) was 100%.

200

201 **Participant Characteristics in SH study**

202 Table 1 summarizes SH study participant characteristics. In total 534
203 individuals had UWF retinal images captured. Two participants [4 eyes] proved
204 difficult to scan and images were not obtained. This left 532 pairs of eyes for
205 grading. The mean age was 58 years (range=27-75, SD 9.5) with 425 (80%)
206 aged over 50 years. There were 299 males (56%). 178 (33%) had no CAD, 351
207 (66%) had CAD present, whilst 182 (34%) had hypertension and 42 (24%) had
208 no CAD or hypertension.

209

210 **Intragrader agreement in SH study**

211 The intragrader agreement illustrated in Table 2 gives the kappa range for the AMD
212 features, the presence of RPD ranged from: 0.62-0.76, drusen: 0.58-0.64, maximum
213 drusen size: 0.55-0.62, increased pigment: 0.54-0.61, decreased pigment: 0.55-0.62,
214 GA: 0.62-0.76, neovascular AMD: 0.57-0.66 and peripheral abnormality: 0.55-0.59
215 within zones 1-3. For the lesions which were absent in the cohort the discordance in
216 the grading originated from a change of grade of feature absent to ungradeable
217 between the two gradings.

218

219 **Prevalence of RPD and AMD features in the SH study**

220 RPD was present in one or both eyes of 30 participants (5.6%) and bilateral in 23
221 participants (4.3%). Drusen >125µm were present in 201 participants (38%).
222 Participants with RPD ranged in age from 33-75 years (mean 59) and there were
223 equal numbers of males and females. The other AMD features graded as present in
224 the participants were as follows: 352 (66%) had hyperpigmentation, 55 (10%) had
225 hypopigmentation, 2 (0.4%) had unilateral GA, none of the participant was classified
226 as having neovascular AMD and 183 (34%) showed other non-AMD peripheral
227 abnormalities.

228

229 **Association of CAD with RPD**

230 CAD was present in 20 participants and absent in 10 participants with RPD,
231 however, no statistically significant association between RPD and CAD was found on
232 either the unadjusted or adjusted generalized estimating equations (GEE) model
233 ($p>0.05$, Table 3). With respect to associations between RPD and other early AMD
234 features a strong association was noted with drusen >125µm in the fully adjusted
235 model. Eighteen participants had both RPD and drusen >125µm, while 11
236 participants had RPD alone without evidence of soft drusen.

237

238 **DISCUSSION**

239 This is the first study to report the prevalence of RPD from a cohort drawn from a
240 cardiovascular clinical setting which had also captured UWF retinal images thus
241 allowing an examination of potential associations . Contrary to previous reports, we
242 failed to find a significant association between RPD and the presence of

243 anatomically defined CAD.^{24-27,29} Our findings are in accordance with population
244 based studies and some of the clinical cohorts that did not report significant
245 associations between RPD and CAD or hypertension.^{17-19,21-23} In fact, the
246 prevalence of RPD observed in the current study (30 out of 534 participants - 5.6%)
247 is similar to that reported by the population based Rotterdam study (4.9%),¹⁸
248 providing additional support for the view that CAD is not associated with an
249 increased prevalence of RPD.

250

251 While 80% of participants were aged over 50, a common age restriction for many
252 AMD studies, interestingly 8 participants with RPD were aged under 50, the
253 youngest aged 33. Of these 4 (50%) also had evidence of drusen >125µm whereas
254 the rest had no other features of AMD present. In the overall sample, 7 participants
255 had RPD without any other AMD features similar to previous observations,¹⁸ which
256 may reflect a different phenotype given that RPD have been reported in other retinal
257 diseases such as Sorsby fundus dystrophy, pseudoxanthoma elasticum and
258 acquired vitelliform lesions.³⁵⁻³⁷ Given the rarity of these participants, it is likely that
259 studies of large sample size or pooled analyses across studies will be required to
260 improve our understanding of the relevance of these isolated RPD.

261

262 This is also the second study, to our knowledge, that used UWF imaging for the
263 evaluation of RPD.³⁰ The validation protocols implemented using NICOLA image
264 data confirmed the reliability of this approach to detect the reticular pattern that has
265 been observed when using other *en face* modalities such as IR or AF imaging.
266 Nonetheless we are of the view that as with other *en face* modalities color UWF also
267 underestimates the prevalence because the earliest stages of this phenotype of SDD

268 is best appreciated on high resolution SD OCT.³⁸ Stage one SDD is defined by the
269 dispersed nature of the deposits of granular hyperreflective material that is present
270 in the outer retina in the region of the photoreceptors' inner and outer segments (the
271 IS/OS boundary) and the retinal pigment epithelium, prior to the characteristic
272 reticulated pattern that accompanies stages 2 and 3, which have been attributed to
273 focal deposits that cause marked alterations to the IS/OS boundary and thus
274 become detectable by en face imaging.³⁸ Currently it is accepted that detection of
275 RPD is best when a multimodal approach, combining infra-red reflectance, AF and
276 SD-OCT are used.^{23,39} We were however reassured by the validation study which
277 demonstrated the benefit of the increased field of view provided by UWF imaging
278 and that RPD was evident in at least one participant in the retinal fundus in an area
279 that is typically not evaluated in AMD studies using CFP (35° or 45°), raising the
280 possibility of under ascertainment when the evaluated images are restricted to the
281 central fundus.

282

283 A potential limitation of this study is the choice of controls and the few RPD cases,
284 as all recruits were attending the cardiology clinic for suspected angina. However the
285 trial participants were recruited from a Chest pain clinic, and they were subsequently
286 classified as having no CAD on the basis of clinical examination, computed
287 tomography coronary angiography and calcium scores. Whether this cohort is
288 representative of what may be observed in a random population based sample is
289 unclear. Even though we adjusted for age, sex and the presence of smoking, given
290 the focus of the SH trial, some of the traditional AMD risk factors, such as diet and
291 known genetic risk variants, were not available and therefore residual confounding
292 may be present.

293

294 In conclusion, our study does not support previously reported associations with CAD,
295 yet the strong association observed with other AMD features in this non-AMD cohort
296 highlights the necessity for improved understanding of the mechanisms and
297 ethiology of this intriguing phenotype. To do so, more data from large and well
298 characterized longitudinal population based studies with multimodal imaging will be
299 required. In addition, pooled analyses of multiple studies to improve statistical power
300 may help untangle the complexity of the risk factors and sub-phenotypes involved.

301

302 **Acknowledgements:**

303 The Chief Scientist Office of the Scottish Government Health and Social Care
304 Directorates funded the SCOT-HEART trial with supplementary awards from
305 Edinburgh and Lothian's Health Foundation Trust and the Heart Diseases
306 Research Fund. We are grateful to the participants of the Northern Ireland Cohort for
307 the longitudinal study of ageing (NICOLA), and the NICOLA team, which includes
308 nursing staff, research scientists, clerical staff, computer and laboratory technicians,
309 managers and receptionists. We acknowledge funding support from Atlantic
310 Philanthropies, Economic and Social Research Council, Health and Social Care
311 Research and Development, United Kingdom Clinical Research Collaboration and
312 Queen's University Belfast who provided core financial support for NICOLA. The
313 authors alone are responsible for the interpretation of the data and any views or
314 opinions presented are solely those of the author and do not necessarily represent
315 those of the NICOLA steering committee.

316

317

318 **References**

- 319 1. Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific
320 prevalence and causes of blindness and visual impairment in an older population:
321 The Rotterdam study. *Arch Ophthalmol*. 1998;116:653-658.
- 322 2. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular
323 degeneration: Pooled findings from three continents. *Ophthalmology*. 2001;108:697-
324 704.
- 325 3. Hogg RE, Woodside JV, Gilchrist SE, et al. Cardiovascular disease and
326 hypertension are strong risk factors for choroidal neovascularization. *Ophthalmology*.
327 2008;115:1046-1052. e2.
- 328 4. Wu J, Uchino M, Sastry SM, Schaumberg DA. Age-related macular degeneration
329 and the incidence of cardiovascular disease: A systematic review and meta-analysis.
330 *PLoS ONE*. 2014;9:e102216.
- 331 5. Wieberdink RG, Ho L, Ikram MK, et al. Age-related macular degeneration and the
332 risk of stroke: The Rotterdam study. *Stroke*. 2011;42:2138-2142.
- 333 6. Seddon JM, Cote J, Davis N, Rosner B. Progression of age-related macular
334 degeneration: Association with body mass index, waist circumference, and waist-hip
335 ratio. *Arch Ophthalmol*. 2003;121:785-792.
- 336 7. Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of
337 cigarette smoking and age-related macular degeneration in women. *JAMA*.
338 1996;276:1141-1146.

- 339 8. Klein R, Klein BE, Tomany SC, Meuer SM, Huang G. Ten-year incidence and
340 progression of age-related maculopathy: The Beaver Dam eye study.
341 *Ophthalmology*. 2002;109:1767-1779.
- 342 9. Curcio CA, Millican CL, Bailey T, Kruth HS. Accumulation of cholesterol with age
343 in human bruch's membrane. *Invest Ophthalmol Vis Sci*. 2001;42:265-274.
- 344 10. Klaver CC, Kliffen M, van Duijn CM, et al. Genetic association of apolipoprotein E
345 with age-related macular degeneration. *The American Journal of Human Genetics*.
346 1998;63:200-206.
- 347 11. Smailhodzic D, Klaver CC, Klevering BJ, et al. Risk alleles in CFH and ARMS2
348 are independently associated with systemic complement activation in age-related
349 macular degeneration. *Ophthalmology*. 2012;119:339-346.
- 350 12. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-
351 related macular degeneration. *Science*. 2005; 308:385-389.
- 352 13. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between C-
353 reactive protein and age-related macular degeneration. *JAMA*. 2004;291:704-710.
- 354 14. Finger RP, Wu Z, Luu CD, et al. Reticular pseudodrusen: A risk factor for
355 geographic atrophy in fellow eyes of individuals with unilateral choroidal
356 neovascularization. *Ophthalmology*. 2014;121:1252-1256.
- 357 15. Marsiglia M, Boddu S, Bearely S, et al. Association between geographic atrophy
358 progression and reticular pseudodrusen in eyes with dry age-related macular
359 degeneration. *Invest Ophthalmol Vis Sci*. 2013;54:7362-7369.

- 360 16. Cohen SY, Dubois L, Tadayoni R, Delahaye-Mazza C, Debibie C, Quentel G.
361 Prevalence of reticular pseudodrusen in age-related macular degeneration with
362 newly diagnosed choroidal neovascularisation. *Br J Ophthalmol*. 2007;91:354-359.
- 363 17. Wu Z, Ayton LN, Luu CD, Baird PN, Guymer RH. Reticular pseudodrusen in
364 intermediate age-related macular degeneration: Prevalence, detection, clinical,
365 environmental, and genetic associations. *Invest Ophthalmol Vis Sci*. 2016;57:1310-
366 1316.
- 367 18. Buitendijk GH, Hooghart AJ, Brussee C, et al. Epidemiology of reticular
368 pseudodrusen in age-related macular degeneration: The Rotterdam study. *Invest*
369 *Ophthalmol Vis Sci*. 2016;57:5593-5601.
- 370 19. Finger RP, Chong E, McGuinness MB, et al. Reticular pseudodrusen and their
371 association with age-related macular degeneration: The Melbourne collaborative
372 cohort study. *Ophthalmology*. 2016;123:599-608.
- 373 20. Hogg RE, Silva R, Staurenghi G, et al. Clinical characteristics of reticular
374 pseudodrusen in the fellow eye of patients with unilateral neovascular age-related
375 macular degeneration. *Ophthalmology*. 2014;121:1748-1755.
- 376 21. Zarubina AV, Neely DC, Clark ME, et al. Prevalence of subretinal drusenoid
377 deposits in older persons with and without age-related macular degeneration, by
378 multimodal imaging. *Ophthalmology*. 2016;123:1090-1100.
- 379 22. Huisingh C, McGwin G, Neely D, et al. The association between subretinal
380 drusenoid deposits in older adults in normal macular health and incident age-related
381 macular degeneration. *Invest Ophthalmol Vis Sci*. 2016;57:739-745.

- 382 23. Chan H, Cougnard-Grégoire A, Delyfer M, et al. Multimodal imaging of reticular
383 pseudodrusen in a population-based setting: The Alienor study. *Invest Ophthalmol*
384 *Vis Sci.* 2016;57:3058-3065.
- 385 24. Cymerman RM, Skolnick AH, Cole WJ, Nabati C, Curcio CA, Smith RT.
386 Coronary artery disease and reticular macular disease, a subphenotype of early age-
387 related macular degeneration. *Curr Eye Res.* 2016;1:1482-1488.
- 388 25. Rastogi N, Smith RT. Association of age-related macular degeneration and
389 reticular macular disease with cardiovascular disease. *Surv Ophthalmol.* 2015;
390 61:422-433.
- 391 26. Klein R, Meuer SM, Knudtson MD, Iyengar SK, Klein BE. The epidemiology of
392 retinal reticular drusen. *Am J Ophthalmol.* 2008;145(2):317-326. e1.
- 393 27. Boddu S, Lee MD, Marsiglia M, Marmor M, Freund KB, Smith RT. Risk factors
394 associated with reticular pseudodrusen versus large soft drusen. *Am J Ophthalmol.*
395 2014;157:985-993. e2.
- 396 28. Smith RT, Merriam JE, Sohrab MA, et al. Complement factor H 402H variant and
397 reticular macular disease. *Arch Ophthalmol.* 2011;129:1061-1066.
- 398 29. Smith RT, Sohrab MA, Busuioc M, Barile G. Reticular macular disease. *Am J*
399 *Ophthalmol.* 2009;148:733-743. e2.
- 400 30. Domalpally A, Clemons TE, Danis RP, et al. Peripheral retinal changes
401 associated with age-related macular degeneration in the age-related eye disease
402 study 2: Age-related eye disease study 2 report number 12 by the age-related eye

403 disease study 2 optos peripheral retina (OPERA) study research group.
404 *Ophthalmology*. 2017;S0161-6420:31491-31499.

405 31. Newby DE, Williams MC, Hunter A, et al. CT coronary angiography in patients
406 with suspected angina due to coronary heart disease (SCOT-HEART): an open-
407 label, parallel group, multicentre trial. *Lancet*. 2015;385:2383-2391.

408 32. Pellegrini E, Robertson G, Trucco E, et al. Blood vessel segmentation and width
409 estimation in ultra-wide field scanning laser ophthalmoscopy. *Biomed Opt Express*.
410 2014; 5:4329-4337.

411 33. University of Wisconsin Fundus Photograph Reading Center. Study-specific
412 grading procedures for OPERA study. 2013.


413 34. Landis JR, Koch GG. The measurement of observer agreement for categorical
414 data. *Biometrics*. 1977;33(1):159-174.

415 35. Gliem M, Hendig D, Finger RP, Holz FG, Issa PC. Reticular pseudodrusen
416 associated with a diseased bruch membrane in pseudoxanthoma elasticum. *JAMA*
417 *Ophthalmology*. 2015;133:581-588.

418 36. Gliem M, Müller PL, Mangold E, et al. Reticular pseudodrusen in sorsby fundus
419 dystrophy. *Ophthalmology*. 2015;122:1555-1562.

420 37. Freund KB, Laud K, Lima LH, Spaide RF, Zweifel S, Yannuzzi LA. Acquired
421 vitelliform lesions: Correlation of clinical findings and multiple imaging analyses.
422 *Retina*. 2011;31:13-25.


- 423 38. Zweifel SA, Spaide RF, Curcio CA, Malek G, Imamura Y. Reticular
424 pseudodrusen are subretinal drusenoid deposits. *Ophthalmology*. 2010;117:303-
425 312.e1.
- 426 39. Schaal KB, Legarreta AD, Feuer WJ, et al. Comparison between widefield en
427 face swept-source OCT and conventional multimodal imaging for the detection of
428 reticular pseudodrusen. *Ophthalmology*. 2016.



430

431 **Figure 1: The Modified SOCA Grid utilized on the Optos Software.**

432 Z1 and Z2 are each divided into four quadrants: superonasal (SN), superotemporal
 433 (ST), inferotemporal (IT), and inferonasal (IN). Z3 is divided into two hemispheres
 434 (superior, inferior) using a visual extension of the horizontal cross line (yellow
 435 dashed lines). Taken from the Study-Specific Grading Procedures for OPERA,
 436 University of Wisconsin (2013).³³




437

438 **Figure 2: Optos ultra-widefield retinal image grading grids for specific AMD**
 439 **characteristics.**

440 The SOCA grid is divided into three zones: Zone 1 (posterior pole), Zone 2 (extends
 441 from Z1 to a circle through the ampullae of the vortex veins) and Zone 3 (extends
 442 from Z2 to the outer periphery). The Manchester grid was superimposed onto the
 443 SOCA grid to assess the ungradable areas.

444

445




446

447 **Figure 3: Optos ultra-widefield retinal image illustrating RPD.**

448 RPD is a subtype of AMD associated with subretinal drusenoid deposits located

449 between the retinal pigment epithelium and the inner ellipsoid zone.

450



451

452 **Figure 4** shows the RPD interlacing pattern on both the UWF and fundus camera
 453 image. **A.** UWF pseudo color image showing RPD (black circle). **B.** UWF green laser
 454 imaging with RPD visible within the black circle. **C.** Fundus camera image with RPD
 455 within the black circle. **D.** UWF pseudo color image with arrows pointing to areas of
 456 RPD. **E.** UWF green laser imaging with arrows annotating areas of RPD. In this case
 457 RPD was detected beyond the field of view of color fundus photography. **F.**

458 Corresponding fundus camera image with no readily visible RPD within the black
459 circle.

460
461

Table 1. Summary statistics for study participants.

	All participants N=534	Reticular Pseudodrusen (1 or both eyes)		
		Absent N=504	Present N=30	P
Age Mean (SD)	58 (10)	58 (9)	59 (12)	0.76
Sex (%) Male Female	299 (56) 235 (44)	284 (56) 220 (44)	15 (50) 15 (50)	0.57
BMI Mean (SD)	30 (7)	30 (7)	28 (6)	0.19
CAD diagnosis (%) None Non-Obstructive-Mild Non-Obstructive-Moderate Obstructive CAD Missing	178 (33) 114 (21) 87 (16) 150 (28) 5 (1)	168 (33) 105 (21) 84 (17) 142 (28) 5(1)	10 (33) 9 (30) 3 (10) 8 (27) 0 (0)	0.71
CAD (%) Absent Present Missing	178 (33) 351 (66) 5 (1)	168 (33) 331 (66) 5 (1)	10 (33) 20 (67) 0 (0)	0.99
Assign Score Mean (SD)	18 (12)	18 (12)	17 (11)	0.56
Coronary Artery Calcium Score Mean (SD)	314 (805)	310 (814)	376 (634)	0.67
Hypertension (%) No Yes Missing	346 (65) 182 (34) 6 (1)	327 (65) 171 (34) 6 (1)	19 (63) 11 (37) 0 (0)	0.84
Diabetes (Type1 or 2) (%) No Yes	483 (90) 51 (10)	455 (90) 49 (10)	28 (93) 2 (7)	0.76
Drusen >125µm (%) Absent Present Missing	330 (62) 201 (38) 3 (1)	319 (63) 183 (36) 2 (1)	11 (37) 18 (60) 1 (3)	0.01
Smoking History (%) Never Ex-smoker Current Smoker	256 (48) 193 (36) 85 (16)	244 (48) 183 (36) 77 (15)	12 (40) 10 (33) 8 (27)	0.25

462
463

464 **Table 2.** Intragrader agreement for the individual age-related macular
 465 degeneration phenotypes.

AMD Characteristic	Kappa Range		
	Zone 1	Zone 2	Zone 3
Neovascular AMD	0.66	0.57	0.61
Increased Pigment	0.59	0.54	0.61
Decreased Pigment	0.66	0.55	0.62
Geographic Atrophy	0.66	0.76	0.62
Drusen	0.59	0.64	0.58
Maximum Drusen Size	0.60	0.62	0.55
Reticular Pseudodrusen	0.67	0.76	0.62
Peripheral Abnormality	N/A	0.59	0.55
Presence of other Pathology (All zones)	0.62		

466

467

468 **Table 3** – Investigation of coronary artery disease as a risk factor for reticular
 469 pseudodrusen using generalized estimating equations.

470

	Unadjusted model			Age and Sex adjusted			Multivariate adjusted*		
	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P
CAD	1.30	0.58-2.92	0.52	1.33	0.57-3.11	0.52	1.31	0.57-3.01	0.52
Age				1.01	0.95-1.07	0.78	1.00	0.95-1.06	0.92
Sex				1.51	0.67-3.40	0.32	1.40	0.62-3.14	0.42
Drusen >125 μm							3.18	1.61-6.27	0.001

471

472 *Multivariate model was adjusted for age, sex and smoking status.

473